Bioqual (OTCMKTS:BIOQ – Get Free Report) posted its quarterly earnings results on Thursday. The company reported ($0.56) earnings per share (EPS) for the quarter, Zacks reports. Bioqual had a negative return on equity of 11.20% and a negative net margin of 9.75%.
Bioqual Price Performance
Shares of OTCMKTS:BIOQ remained flat at $30.64 on Thursday. The stock had a trading volume of 900 shares, compared to its average volume of 3. The stock has a market cap of $27.27 million, a PE ratio of -7.03 and a beta of -0.10. The firm has a fifty day simple moving average of $32.86 and a 200 day simple moving average of $33.70. Bioqual has a one year low of $30.64 and a one year high of $43.55.
Bioqual Company Profile
Bioqual, Inc is a biomedical research and contract research organization based in Rockville, Maryland. The company provides preclinical research services to pharmaceutical and biotechnology companies, government agencies, and other organizations involved in the development of medical products.
Its work focuses primarily on infectious diseases, vaccines, therapeutics, and diagnostics. Bioqual conducts laboratory and animal-model studies designed to evaluate the safety, efficacy, immunology, virology, and pharmacology of potential treatments and preventive products.
See Also
- Five stocks we like better than Bioqual
- Flywire’s Rapid Growth Faces a Q3 Test—Is Its Stock Already Too Expensive?
- Cologuard Is Working—So Why Isn’t Abbott Stock?
- Micron’s Taiwan Strike: A High-Stakes Fight Over AI Profits
- Intuitive Surgical Stock: Margin Hit Masks Strong Q3 Growth Story
Receive News & Ratings for Bioqual Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioqual and related companies with MarketBeat.com's FREE daily email newsletter.
